{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:54:21Z","timestamp":1787828061345,"version":"build-2784847793"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013209","name":"HFRI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003448","name":"General Secretariat for Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003448","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["938"],"award-info":[{"award-number":["938"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009043","name":"University of Patras","doi-asserted-by":"publisher","award":["BAY 41-2272"],"award-info":[{"award-number":["BAY 41-2272"]}],"id":[{"id":"10.13039\/100009043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bioorg.2024.107170","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T11:18:34Z","timestamp":1706872714000},"page":"107170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification of new multi-substituted 1H-pyrazolo[3,4-c]pyridin-7(6H)-ones as soluble guanylyl cyclase (sGC) stimulators with vasoprotective and anti-inflammatory activities"],"prefix":"10.1016","volume":"144","author":[{"given":"Dionysios-Panagiotis","family":"Kintos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Salagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiris S.","family":"Nikolaropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Topouzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis A.","family":"Fousteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2024.107170_b0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.bioorg.2024.107170_b0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Resp Med."},{"key":"10.1016\/j.bioorg.2024.107170_b0015","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1111\/j.1460-9568.2008.06285.x","article-title":"Concepts of neural nitric oxide-mediated transmission","volume":"27","author":"Garthwaite","year":"2008","journal-title":"Eur J Neurosci."},{"key":"10.1016\/j.bioorg.2024.107170_b0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","article-title":"Structure and regulation of soluble guanylate cyclase","volume":"81","author":"Derbyshire","year":"2012","journal-title":"Annu Rev Biochem."},{"key":"10.1016\/j.bioorg.2024.107170_b0025","doi-asserted-by":"crossref","first-page":"e50634","DOI":"10.7554\/eLife.50634","article-title":"Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electon microscopy","volume":"8","author":"Horst","year":"2019","journal-title":"eLife."},{"key":"10.1016\/j.bioorg.2024.107170_b0030","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.bioorg.2024.107170_b0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-540-68964-5_9","article-title":"cGK substrates","volume":"191","author":"Schlossmann","year":"2009","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107170_b0040","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1038\/ncomms9482","article-title":"Cardiovascular and pharmacological implications of heam-deficient NO-unresponsive soluble guanylate cyclase knock-in mice","volume":"6","author":"Thoonen","year":"2015","journal-title":"Nat Commun."},{"key":"10.1016\/j.bioorg.2024.107170_b0045","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1038\/ncomms8235","article-title":"Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue","volume":"6","author":"Hoffmann","year":"2015","journal-title":"Nat Commun."},{"key":"10.1016\/j.bioorg.2024.107170_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101832","article-title":"An inherent dysfunction on soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling","volume":"39","author":"Ghosh","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.bioorg.2024.107170_b0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.niox.2018.10.006","article-title":"Pharmacological manipulation of cGMP and NO\/sGC\/cGMP in CNS drug discovery","volume":"82","author":"Hollas","year":"2019","journal-title":"Nitric Oxide."},{"key":"10.1016\/j.bioorg.2024.107170_b0060","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107170_b0065","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-642-38664-0_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"218","author":"Stasch","year":"2013","journal-title":"Hand Exp Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107170_b0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-3-540-68964-5_14","article-title":"NO- and haem-independent soluble guanylate cyclase activators","volume":"191","author":"Schmidt","year":"2009","journal-title":"Handb Exp Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107170_b0075","first-page":"287","article-title":"cGMP: a unique 2nd messenger molecule \u2013 recent developments in cGMP research and development","volume":"393","author":"Friebe","year":"2020","journal-title":"N-S Acrh Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107170_b0080","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1002\/anie.201302588","article-title":"The chemistry and biology of soluble guanylate cyclase stimulators and activators","volume":"52","author":"Follman","year":"2013","journal-title":"Angew Chem Int Ed."},{"key":"10.1016\/j.bioorg.2024.107170_b0085","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1177\/0091270008322906","article-title":"Pharmacokinetics, pharmacodynamics, tolerability and safety of the soluble guanylate cyclase activator Cinaciguat (BAY 58\u20132667) in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107170_b0090","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.bioorg.2024.107170_b0095","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619868938","article-title":"Practical management of riociguat in patients with pulmonary arterial hypertension","volume":"13","author":"Halank","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.bioorg.2024.107170_b0100","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/eurjhf\/hfs093","article-title":"Cinaciguat, a soluble guanylate cyclase activator: results form the randomized, controlled, phase IIb COMPOSE programme in acute heart failure","volume":"14","author":"Gheorghiade","year":"2012","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.bioorg.2024.107170_b0105","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bcp.2019.02.007","article-title":"A novel soluble guanylyl cyclase activator, BR 11257, acts as a nonstabilising partial agonist of sGC","volume":"163","author":"Elgert","year":"2019","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107170_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173203","article-title":"Tyrosine 135 of the \u03b21 subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugs","volume":"881","author":"Ruhle","year":"2020","journal-title":"Eur J Pharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107170_b0115","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the soluble guanylate cyclase activator runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J Med Chem."},{"key":"10.1016\/j.bioorg.2024.107170_b0120","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226","article-title":"YC-1, a novel activator of platelet guanylate cyclase","volume":"84","author":"Ko","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.107170_b0125","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of Riociguat (BAY 63\u20132521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Mittendorf","year":"2009","journal-title":"ChemMedChem."},{"key":"10.1016\/j.bioorg.2024.107170_b0130","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follman","year":"2017","journal-title":"J Med Chem."},{"key":"10.1016\/j.bioorg.2024.107170_b0135","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur Respir J."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107170_b0140","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2213-2600(16)30022-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial","volume":"4","author":"Simonneau","year":"2016","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.bioorg.2024.107170_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.bioorg.2024.107170_b0150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.niox.2018.05.009","article-title":"Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential","volume":"78","author":"Buys","year":"2018","journal-title":"Nitric Oxide."},{"key":"10.1016\/j.bioorg.2024.107170_b0155","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","article-title":"Chen L Activation mechanism of human soluble guanylate cyclase by stimulators and activators","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bioorg.2024.107170_b0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0960-894X(01)00073-7","article-title":"Furstner C NO-independent stimulators of soluble guanylate cyclase","volume":"11","author":"Straub","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107170_b0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/jm001034k","article-title":"Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor","volume":"44","author":"Selwood","year":"2001","journal-title":"Soluble Guanylate Cyclase. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107170_b0170","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/acsmedchemlett.5b00479","article-title":"Discovery of IWP-051, a novel orally bioavailable sGC stimulator with once-daily dosing potential in humans","volume":"7","author":"Nakai","year":"2016","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107170_b0175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jhet.5570380114","article-title":"Preparation of 4-substituted 3-Amino-3-chloropyridines, Synthesis of a Nevirapine Analogue","volume":"38","author":"Bakke","year":"2001","journal-title":"J. Heterocyclic Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107170_b0180","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1248\/cpb.56.775","article-title":"Synthesis and antiviral activity evaluation of some novel acyclic C-nucleosides","volume":"56","author":"Lougiakis","year":"2008","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2024.107170_b0185","unstructured":"Yao Q, Xu Y, Wu S, Inventors; Pyrazolopyridine compound and preparation method thereof, CN103992318B, 2016."},{"key":"10.1016\/j.bioorg.2024.107170_b0190","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1039\/C4OB01951B","article-title":"Microwave-assisted preparation of 4-amino-3-cyano-5-methoxycarbonyl-N-arylpyrazozoles as building blocks for the diversity-oriented synthesis of pyrazole-based polycyclic scaffolds","volume":"13","author":"Le Corre","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2024.107170_b0195","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.crstbi.2021.11.003","article-title":"Replacement of heme by soluble guanylate cyclase (sGC) activators abolishes heme-nitric oxide\/oxygen (H-NOX) domain structural plasticity","volume":"3","author":"Argyriou","year":"2021","journal-title":"Curr. Res. Struct. Biol."},{"key":"10.1016\/j.bioorg.2024.107170_b0200","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fphar.2012.00010","article-title":"Phosphodiesterases regulate BAY 41\u20132272-induced VASP phosphorylation in vascular smooth muscle cells","volume":"3","author":"Adderley","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107170_b0205","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cellsig.2016.06.012","article-title":"Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation","volume":"28","author":"Holt","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2024.107170_b0210","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/164_2018_197","article-title":"Soluble guanylate cyclase stimulators and activators","volume":"264","author":"Sandner","year":"2021","journal-title":"Hand. \u0395xp. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107170_b0215","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, anti-inflammatory and antifibrotic effects in preclinical models of disease","volume":"365","author":"Tobin","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107170_b0220","doi-asserted-by":"crossref","first-page":"H1763","DOI":"10.1152\/ajpheart.51.2008","article-title":"Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress","volume":"295","author":"Zhou","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107170_b0225","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/biomedicines8090330","article-title":"BAY 41\u20132272 Attenuates CTGF Expression via sGC\/cGMP \u2013 Independent Pathway in TGF\u03b21-Activated Hepatic Stellate Cells","volume":"8","author":"Chen","year":"2020","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107170_b0230","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41598-017-01392-1","article-title":"Hypertension reduces soluble guanylyl cyclase expression in the mouse aorta via the Notch signaling pathway","volume":"7","author":"Rippe","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.107170_b0235","doi-asserted-by":"crossref","unstructured":"Pan SL, Guh JH, Chang YL, Kuo SC, Lee FY, Teng CM. YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovasc. Res. 2004;):152-158. doi: 10.1016\/j.cardiores.2003.09.013.","DOI":"10.1016\/j.cardiores.2003.09.013"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107170_b0240","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1124\/jpet.111.183400","article-title":"The soluble guanylate cyclase stimulator BAY 41\u20132272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways","volume":"339","author":"Joshi","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107170_b0245","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1073\/pnas.0304264101","article-title":"Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment","volume":"101","author":"Ahluwalia","year":"2004","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107170_b0250","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/labinvest.3780446","article-title":"Leukocyte-Endothelial cell interactions in the inflammatory response","volume":"82","author":"Muller","year":"2002","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107170_b0255","doi-asserted-by":"crossref","first-page":"e14525","DOI":"10.1371\/journal.pone.0014525","article-title":"Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils","volume":"6","author":"Zhang","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2024.107170_b0260","doi-asserted-by":"crossref","unstructured":"a) OEDOCKING 4.1.2: OpenEye Scientific Software, Inc., Santa Fe, NM. http:\/\/www.eyesopen.com, b) Kelley BP, Brown SP, Warren GL, Muchmore SW. POSIT: Flexible Shape-Guided Docking For Pose Prediction. J. Chem. Inf. Model. 2015;55:1771-1780. doi: 10.1021\/acs.jcim.5b00142, c) McGann M. FRED Pose Prediction and Virtual Screening Accuracy. J. Chem. Inf. Model. 2011;51:578-596. doi: 10.1021\/ci100436p, d) McGann M. J. FRED and HYBRID docking performance on standardized datasets. J. Comput. Aided Mol. Des. 2012;26:897-906. doi: 10.1007\/s10822-012-9584-8.","DOI":"10.1007\/s10822-012-9584-8"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107170_b0265","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1073\/pnas.051631298","article-title":"Spatiotemporal dynamics of guanosine 3',5'-cyclic monophosphate revealed by a genetically encoded, fluorescent indicator","volume":"98","author":"Honda","year":"2001","journal-title":"PNAS USA"},{"issue":"10","key":"10.1016\/j.bioorg.2024.107170_b0270","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/ijms17101672","article-title":"Modulation of compartmentalised cyclic nucleotide signalling via local inhibition of phosphodiesterase activity","volume":"17","author":"Brescia","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107170_b0275","doi-asserted-by":"crossref","unstructured":"a) OMEGA 4.2.0: OpenEye Scientific Software, Santa Fe, NM.http:\/\/www.eyesopen.com. b) Hawkins PC, Skillman AG, Warren GL, Ellingson BA, and Stahl MT. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model. 2010;50:572\u2010584. doi: 10.1021\/ci100031x.","DOI":"10.1021\/ci100031x"},{"key":"10.1016\/j.bioorg.2024.107170_b0280","unstructured":"BIOVIA, Dassault Syst\u00e8mes, Discovery Studio Visualizer, v21.1.0.20298, San Diego: Dassault Syst\u00e8mes, 2020."},{"key":"10.1016\/j.bioorg.2024.107170_b0285","unstructured":"The PyMOL Molecular Graphics System, Version 2.5.3 Schr\u00f6dinger, LLC."},{"key":"10.1016\/j.bioorg.2024.107170_b0290","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1016\/j.bmc.2009.05.015","article-title":"Design, synthesis and dopamine D4 receptor binding activities of new N-heteroaromatic 5\/6-ring Mannich bases","volume":"17","author":"Linz","year":"2009","journal-title":"Bioorg Med Chem."},{"key":"10.1016\/j.bioorg.2024.107170_b0295","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1021\/jo0155613","article-title":"Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: convergent synthesis of the aza-C-nucleoside immucillins","volume":"66","author":"Evans","year":"2001","journal-title":"J Org Chem."},{"key":"10.1016\/j.bioorg.2024.107170_b0300","doi-asserted-by":"crossref","unstructured":"Chapman D, Hurst J. Pyrazolopyridines. Part 5. Preparation and reactions of pyrazolo[3,4-c]pyridines. J. Chem. Soc., Perkin Trans. 1. 1980;0:2398-2404. doi: 10.1039\/P19800002398.","DOI":"10.1039\/p19800002398"},{"key":"10.1016\/j.bioorg.2024.107170_b0305","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.bjp.0707534","article-title":"Anti-angiogenic properties of a sulindac analogue","volume":"152","author":"Pyriochou","year":"2007","journal-title":"Br J Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107170_b0310","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/jpet.114.222000","article-title":"ATP-sensitive potassium channel activation induces angiogenesis in vitro and in vivo","volume":"354","author":"Umaru","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107170_b0315","doi-asserted-by":"crossref","first-page":"R824","DOI":"10.1152\/ajpregu.00222.2009","article-title":"The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability","volume":"298","author":"Morbidelli","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:57:13Z","timestamp":1777463833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":63,"alternative-id":["S0045206824000750"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107170","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of new multi-substituted 1H-pyrazolo[3,4-c]pyridin-7(6H)-ones as soluble guanylyl cyclase (sGC) stimulators with vasoprotective and anti-inflammatory activities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107170"}}